SMO and medulloblastoma: Combinatory inhibition of both PI3K and HH signaling pathways in preclinical studies on medulloblastoma have demonstrated favorable efficacy in attenuating SMO inhibitor-resistant tumors (36), although the effects on other HH-mediated cancers like BCC remains to be determined.